Pathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Unraveling the role of autoantibodies in rheumatoid arthritis: Toward personalized treatment
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
What you’ll learn:
- How integrated proteomic and immunological profiling uncovers distinct RA subtypes
- The role of autoantibodies in tracking disease progression and predicting treatment outcomes using KREX™ technology
- New molecular insights into RA pathology and therapeutic targeting opportunities
Whether you’re researching autoimmune mechanisms or exploring novel diagnostics and treatments, this session offers valuable perspectives from the frontlines of proteomics and precision medicine.
Watch now and take the next step in understanding RA at the molecular level.
Allan Stensballe, PhD
Aalborg University
Allan Stensballe is a distinguished researcher in the field of proteomics, focused on elucidating the molecular mechanisms underlying autoimmune disorders like RA. By integrating advanced proteomic technologies – such as nanoproteomics and protein array-based diagnostics – with clinical and immunological data, his pioneering work has significantly advanced personalized medicine by identifying disease biomarkers, exploring the role of the extracellular matrix in RA and informing targeted therapeutic strategies.
Pathways to Digital Health: AI and Omics in Rheumatoid Arthritis
A presentation by Allan Stensballe, PhD
More webinars
WebinarRethinking Neurodegeneration Through Blood-Based Biomarkers
Proteomics is reshaping how we predict, diagnose, and understand neurodegenerative diseases. In this roundtable, leading experts Tony Wyss-Coray, PhD, and Jacob Vogel, PhD, explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets using the SomaScan™ Assay. They discuss how protein signatures can reveal brain aging, predict dementia, and track changes in disease pathways over time, with moderation by Steve Williams, MD, PhD. Learn how cutting-edge proteomics is redefining what is possible in neurological research.
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.